Heatwurx Inc. (NASDAQ:PCSA) Short Interest Down 36.4% in December

Heatwurx Inc. (NASDAQ:PCSA) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 3,454,719 shares, a drop of 36.4% from the November 30th total of 5,434,144 shares. Based on an average daily volume of 1,992,460 shares, the short-interest ratio is currently 1.7 days. Currently, 156.2% of the shares of the company are sold short. Currently, 156.2% of the shares of the company are sold short. Based on an average daily volume of 1,992,460 shares, the short-interest ratio is currently 1.7 days.

Heatwurx Price Performance

Shares of NASDAQ:PCSA opened at $3.92 on Friday. Heatwurx has a 1-year low of $2.74 and a 1-year high of $27.00. The company has a market capitalization of $8.88 million, a P/E ratio of -0.12 and a beta of 1.09. The firm’s 50 day simple moving average is $6.74 and its two-hundred day simple moving average is $6.22.

Heatwurx (NASDAQ:PCSA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($1.75) EPS for the quarter, topping the consensus estimate of ($2.00) by $0.25. On average, sell-side analysts anticipate that Heatwurx will post -4.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PCSA has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a report on Wednesday, October 8th. HC Wainwright decreased their price target on Heatwurx from $50.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, September 2nd. Finally, Wall Street Zen raised Heatwurx to a “sell” rating in a research report on Saturday, December 20th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $25.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.